Tau and p-tau as CSF biomarkers in dementia: a meta-analysis

Harten, Argonde C. van; Kester, Maartje I.; Visser, Pieter Jelle; Blankenstein, Marinus A.; Pijnenburg, Yolande A.L.; Flier, Wiesje M. van der; Scheltens, Philip

doi:10.1515/cclm.2011.086

Cited by 140 publications

(111 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, tau levels are useful to differentiate VaD from stroke [129] and, as expected, only CJD is characterized by extremely increased tau values, resulting in a sensitivity and specificity over 90% [130].…”

Section: Tausupporting

confidence: 53%

New Frontiers in Alzheimer's Disease Diagnosis

Llorens¹,

Nuhn²,

Peter³

et al. 2015

Alzheimer's Disease - Challenges for the Future

View full text Add to dashboard Cite

Section: Tausupporting

confidence: 53%

New Frontiers in Alzheimer's Disease Diagnosis

Llorens¹,

Nuhn²,

Peter³

et al. 2015

Alzheimer's Disease - Challenges for the Future

View full text Add to dashboard Cite

“…Imaging and cerebrospinal fluid (CSF) biomarkers separately are insensitive to a substantial part of bvFTD patients and show overlap with imaging abnormalities in psychiatric disorders [14,15,16,17,18,19,20,21,22]. Therefore, we aimed to investigate the impact of the clinical package of ancillary investigation (MRI, [ 18 F]-FDG-PET and CSF biomarkers) on the differential diagnostic process of bvFTD and the effect these markers have on diagnostic certainty.…”

Section: Introductionmentioning

confidence: 99%

Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort

Krudop¹,

Dols

Kerssens

et al. 2015

Dement Geriatr Cogn Disord

Self Cite

View full text Add to dashboard Cite

Background: The criteria for behavioral variant frontotemporal dementia (bvFTD) incorporate MRI and [¹⁸F]-FDG-PET. Cerebrospinal fluid (CSF) analysis is merely advised for excluding Alzheimer's disease. Aims: We aimed to assess the impact of biomarkers on diagnostic certainty and contingent changes of bvFTD diagnosis within the clinically relevant neuropsychiatric differential diagnosis of subjects with a late-onset frontal lobe syndrome (LOF). Methods: We included 137 patients with LOF, aged 45-75 years, 72% males. Biomarker disclosure was considered contributing after any substantial difference in diagnostic certainty or a diagnostic change. Percentages of contributing biomarkers were compared between three major diagnostic groups (bvFTD, psychiatry, other neurological disorders). Certainty levels in stable diagnostic groups were compared to those with a diagnostic change. Results: Biomarkers contributed in 53, 60 and 41% of the LOF patients for MRI, [¹⁸F]-FDG-PET and CSF, respectively. Biomarkers changed the diagnosis in 14% of cases towards bvFTD and in 13% from bvFTD into an alternative. Those that changed had a lower level of a priori diagnostic certainty compared to stable diagnoses. Conclusion: Our study not only supports the widely accepted use of MRI and [¹⁸F]-FDG-PET in diagnosing or excluding bvFTD, but also shows that CSF biomarkers aid clinicians in the diagnostic process.

show abstract

“…These PrP C -Aβ plaques have been found in most CJD patients with associated AD-type pathology and it has been proposed that PrP C may promote Aβ plaque formation. 12,13 A genetic correlation between PrP C and AD has also been reported. 14,15 A systematic meta-analysis of AD genetic association studies revealed that the gene encoding PrP C (PRNP) is a potential AD susceptibility gene and the Met/Val 129 polymorphism in PRNP has been determined as a risk factor for early-onset AD.…”

Section: Introductionmentioning

confidence: 88%